IF a combinatorial intervention of progressive resistance exercise training (weighted ladder climbing, 3×/week, 12 weeks, commencing at week 0) followed by intermittent galactose-conjugated navitoclax (Nav-Gal, 10 mg/kg oral gavage on days 1–2 per cycle, every 3 weeks, 4 cycles) is administered to aged male and female C57BL/6J mice (20–22 months, both sexes, n = 20/group),

THEN a synergistic reduction in tissue senescent cell burden (p16^INK4a^+, SA-β-gal+, SASP cytokine panel) exceeding 60% from baseline — greater than either resistance exercise alone (~39% reduction extrapolated from human adipose data) or Nav-Gal alone (~40–50% estimated from navitoclax rodent data) — will be observed across adipose, skeletal muscle, and liver at 12 weeks, accompanied by ≥15% improvement in composite frailty index score, and ≥10% extension of median lifespan compared to aged vehicle controls,

BECAUSE the following mechanistic chain links the two interventions at the molecular level in a genuinely pharmacodynamically synergistic manner:

1. Resistance exercise independently clears senescent cells via immune-mediated mechanisms, reducing circulating SASP markers (IL-6, GDF-15, PAI-1) and p16^INK4a^+ cells — demonstrated in humans where 12 weeks of structured exercise reduced adipose p16^INK4a^+ cells from 5.6% to 2.17% and lowered circulating senescence biomarkers (Exercise reduces circulating biomarkers of cellular senescence)[https://doi.org/10.1111/acel.13415].

2. Resistance exercise upregulates lysosomal biogenesis and SA-β-galactosidase (SA-β-gal) enzymatic activity in residual senescent cells that resist immune clearance — because exercise-induced TFEB activation drives lysosomal expansion, and SA-β-gal is a lysosomal β-galactosidase isoform (GLB1) whose activity scales with lysosomal content [SPECULATIVE — mechanistic link to TFEB/lysosomal biogenesis not directly demonstrated in this context; inferred from lysosomal biology of exercise adaptation].

3. Nav-Gal is a prodrug selectively bioactivated by SA-β-gal (β-galactosidase) in senescent cells, converting to active navitoclax (BCL-2/BCL-xL inhibitor) preferentially within high-β-gal cells — this selectivity was engineered precisely to exploit the elevated SA-β-gal activity that defines senescent cells (Anti-senescent drug screening by deep learning-based morphology senescence scoring)[https://doi.org/10.1038/s41467-020-20213-0].

4. Exercise-primed upregulation of SA-β-gal in residual senescent cells therefore increases local Nav-Gal bioactivation specifically within those cells, creating a pharmacodynamic synergy: exercise enriches the substrate (SA-β-gal activity) that drives selective Nav-Gal activation, thereby targeting a harder-to-clear senescent population that resists exercise-induced immune surveillance alone [SPECULATIVE — direct demonstration of exercise-increased SA-β-gal enhancing prodrug conversion not yet published].

5. **Nav-Gal-mediated BCL-2/BCL-xL inhibition the...

SENS category: RepleniSENS

Key references: • doi.org/10.1111/acel.13415]. • doi.org/10.1038/s41467-020-20213-0]. • doi.org/10.1111/acel.12931]. • doi.org/10.1038/s41467-020-18039-x]. • doi.org/10.1126/science.abe4832].